- Home
- OFS vs ATOS Comparison
OFS vs ATOS Comparison
Compare OFS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- ATOS
- Stock Information
- Founded
- OFS 2001
- ATOS 2009
- Country
- OFS United States
- ATOS United States
- Employees
- OFS N/A
- ATOS N/A
- Industry
- OFS Finance/Investors Services
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- OFS Finance
- ATOS Health Care
- Exchange
- OFS Nasdaq
- ATOS Nasdaq
- Market Cap
- OFS 114.7M
- ATOS 112.5M
- IPO Year
- OFS 2012
- ATOS 2012
- Fundamental
- Price
- OFS $8.61
- ATOS $0.91
- Analyst Decision
- OFS
- ATOS Strong Buy
- Analyst Count
- OFS 0
- ATOS 4
- Target Price
- OFS N/A
- ATOS $6.17
- AVG Volume (30 Days)
- OFS 38.4K
- ATOS 750.1K
- Earning Date
- OFS 07-31-2025
- ATOS 05-13-2025
- Dividend Yield
- OFS 15.78%
- ATOS N/A
- EPS Growth
- OFS N/A
- ATOS N/A
- EPS
- OFS 2.25
- ATOS N/A
- Revenue
- OFS $44,026,000.00
- ATOS N/A
- Revenue This Year
- OFS N/A
- ATOS N/A
- Revenue Next Year
- OFS N/A
- ATOS N/A
- P/E Ratio
- OFS $3.82
- ATOS N/A
- Revenue Growth
- OFS N/A
- ATOS N/A
- 52 Week Low
- OFS $7.75
- ATOS $0.55
- 52 Week High
- OFS $10.01
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- OFS 53.04
- ATOS 58.23
- Support Level
- OFS $8.18
- ATOS $0.83
- Resistance Level
- OFS $8.66
- ATOS $0.90
- Average True Range (ATR)
- OFS 0.25
- ATOS 0.06
- MACD
- OFS 0.01
- ATOS -0.00
- Stochastic Oscillator
- OFS 76.79
- ATOS 70.81
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.